Moderna said at its Analyst Day it targets up to 10% revenue growth in 2026 and expects to expand its seasonal vaccine franchise from 3 to up to 6 approved products by 2028.

1. 01

   Moderna said at its Analyst Day it targets up to 10% revenue growth in 2026 and expects to expand its seasonal vaccine franchise from 3 to up to 6 approved products by 2028.

2. 02

   The company said it is reducing its 2026 and 2027 expected cash costs to approximately $4.2 billion and $3.5 billion to $3.9 billion, respectively, and targets cash breakeven in 2028.

3. 03

   Moderna closed a 5-year term loan facility for up to $1.5 billion from Ares Management Credit Funds and updated its 2025 year-end cash and investment balance outlook to $7.1 billion to $7.6 billion. The company said the prior outlook was $6.5 billion to $7.0 billion and the updated outlook is tied to the $0.6 billion initial loan draw.

4. 04

   Moderna said it is discontinuing 4 programs based on strategic prioritization: mRNA-1647 (congenital CMV), mRNA-1608 (HSV), mRNA-1468 (VZV) and mRNA-3745 (GSD1a). The company also said it targets readouts from 9 ongoing clinical studies in its oncology pipeline.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.